Drug intelligence / Profile preview

cefiderocol

Development stage: Approved
Lead developer: Shionogi
Modality: Small Molecules
Administration: Intravenous

Overview

Cefiderocol is a novel siderophore cephalosporin antibiotic with a unique mechanism of action that allows it to penetrate the outer membrane of Gram-negative bacteria, including multi-drug resistant strains. It is used to treat complicated urinary tract infections and hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia, caused by susceptible Gram-negative bacteria. Developed by Shionogi & Co., Ltd., it was approved by the FDA in November 2019 and by the EU in April 2020.

Brand names: FetrojaFetcroja
Other names: 头孢地尔

Targets

PBP2 (Penicillin-binding protein 2)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on cefiderocol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefiderocol.

Explore the full profile